REPCF (0913693 BC) Days Sales Outstanding: 0.00 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 0913693 BC Days Sales Outstanding?

0913693 BC REPCF Days Sales Outstanding is 0.00 as of Sep. 2023.

0913693 BC's average Accounts Receivable for the three months ended in Sep. 2023 was $0.00 Mil. 0913693 BC's Revenue for the three months ended in Sep. 2023 was $0.07 Mil. Hence, 0913693 BC's Days Sales Outstanding for the three months ended in Sep. 2023 was 0.00.

The historical rank and industry rank for 0913693 BC's Days Sales Outstanding or its related term are showing as below:

REPCF's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.64
* Ranked among companies with meaningful Days Sales Outstanding only.

0913693 BC's Days Sales Outstanding stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00).

0913693 BC  (OTCPK:REPCF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

0913693 BC Days Sales Outstanding Related Terms

0913693 BC Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for 0913693 BC's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

0913693 BC Days Sales Outstanding Chart

0913693 BC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

0913693 BC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

REPCF vs VRTX, REGN, SGEN: Days Sales Outstanding Comparison

For the Biotechnology subindustry, 0913693 BC's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

0913693 BC Days Sales Outstanding vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 0913693 BC's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where 0913693 BC's Days Sales Outstanding falls into.


0913693 BC Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

0913693 BC's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

Days Sales Outstanding (A: Dec. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2021 ) + Accounts Receivable (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )*Days in Period
=( (0 + 0) / 1 ) / 0.261*365
=0 / 0.261*365
=0.00

0913693 BC's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding (Q: Sep. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2023 ) + Accounts Receivable (A: Sep. 2023 )) / count ) / Revenue (A: Sep. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0.065*365 / 4
=0 / 0.065*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Sales Outstanding →
What does a Days Sales Outstanding of 0.00 mean?
0913693 BC (REPCF) has a Days Sales Outstanding of 0.00 as of Sep. 2023. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on 0913693 BC and its competitors.
Is 0913693 BC's Days Sales Outstanding too high?
0913693 BC's current Days Sales Outstanding is 0.00.
How does 0913693 BC's Days Sales Outstanding compare to VRTX and REGN?
0913693 BC's Days Sales Outstanding of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.64, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on 0913693 BC and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 0913693 BC's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 0913693 BC stock overvalued right now?
0913693 BC (REPCF) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For 0913693 BC (REPCF), the current Days Sales Outstanding is 0.00 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

0913693 BC Business Description

Address 570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
0913693 BC Ltd is a regenerative medicine company focused on aesthetics and orthopedics. It is a royalty company that holds its primary royalty assets focused on autologous cell therapies that treat functional cellular deficits, including chronic tendon injuries, androgenetic alopecia, and skin aging. The Company is organized into one business unit based on its cell replication technology and has one reportable operating segment. Its product line is RCT-01 Tendon Repair, RCS-01 Skin Rejuvenation, RCH-01 Hair Growth, and DermaPrecise.